Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.BioWa has entered into an agreement with KaloBios Pharmaceuticals, under which BioWa licenses to KaloBios its Potelligent technology for enhancing the antibody-dependent cellular cytotoxicity of select KaloBios therapeutic antibodies.
Subscribe to our email newsletter
Under the terms of the license agreement, BioWa grants KaloBios non-exclusive rights to research, develop and commercialize therapeutic antibodies generated through Potelligent technology for an undisclosed number of targets. In return, BioWa will receive upfront payment, and may receive development milestone payments and royalties on products.
Potelligent technology improves potency and efficacy of antibody therapeutics, by enhancing antibody-dependent cellular cytotoxicity, one of the major mechanisms of action for antibody therapeutics, said BioWa.
Masamichi Koike, president and CEO of BioWa, said: “We are excited about this strategic partnership with KaloBios. With KaloBios’s specialized expertise in the antibody field, this collaboration will further reinforce our effort to bring the benefit of the technology to patients in need as quickly as possible.”